Description
A Cdk9 inhibitor (IC50 = 5.8 µM for Cdk9/cyclin T1); selective for Cdk9/cyclin T1 over Cdk4/cyclin D3 at 30 µM and Cdk2/cyclin A2, Cdk2/cyclin E1, Cdk5/p25, Cdk6/cyclin D3, and Cdk7/cyclin/MAT1 at 10 µM; inhibits GSK3α, GSK3β, PKN1, haspin, p70S6K, DYRK1B, DYRK3, and IRR at 10 µM; inhibits DNA replication of HSV-1 in HeLa cells (IC50 = 0.69 µM); reduces skin lesions and improves survival in HSV-1-infected mice when applied topically at 1.25-10% w/w; reduces tumor growth in an HPV type 16-positive Ca Ski cervical cancer mouse xenograft model at 300 mg/kg